Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Magnus Gustafsson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 15
Genovis AB (publ.), Annual General Meeting, May 18, 2026 Genovis AB (publ.), Annual General Meeting, May 18, 2026, at 17:00 W. Europe Standard Time. Location: genovis ab office, karl johans vag 104, kavlinge., Sweden Announcement • Feb 12
Genovis AB (publ.) to Report Fiscal Year 2025 Final Results on Apr 23, 2026 Genovis AB (publ.) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 23, 2026 Announcement • Jul 03
Genovis AB (publ.) (OM:GENO) agreed to acquire remaining 75% stake in SEQURNA AB from Björn Reinius and Joyce Noble for SEK 52.5 million. Genovis AB (publ.) (OM:GENO) agreed to acquire remaining 75% stake in SEQURNA AB from Björn Reinius and Joyce Noble for SEK 52.5 million on July 1, 2025. A cash consideration will be paid by Genovis AB (publ.). The consideration for the acquisition of SEQURNA AB by Genovis AB (publ.) is a mix of cash and stock. The consideration consists of issuance of 0.6 million new common equity shares of Genovis AB (publ.) for the common equity of SEQURNA AB. As part of consideration, SEK 52.5 million is paid towards common equity of SEQURNA AB. Upon completion, Genovis AB (publ.) will own 100% stake in SEQURNA AB.
Skandinaviska Enskilda Banken AB acted as financial advisor for Genovis AB. Announcement • May 22
Genovis AB (publ.) to Report Q4, 2025 Results on Feb 12, 2026 Genovis AB (publ.) announced that they will report Q4, 2025 results on Feb 12, 2026 Announcement • Apr 16
Genovis AB (publ.), Annual General Meeting, May 21, 2025 Genovis AB (publ.), Annual General Meeting, May 21, 2025, at 17:00 W. Europe Standard Time. Location: at genovis abs office, karl johans vag 104, kavlinge, Sweden Valuation Update With 7 Day Price Move • Nov 15
Investor sentiment improves as stock rises 37% After last week's 37% share price gain to €2.29, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total loss to shareholders of 72% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.86 per share. New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Profit margins are more than 30% lower than last year (19% net profit margin). Reported Earnings • Nov 10
Third quarter 2024 earnings released: EPS: kr0.21 (vs kr0.048 in 3Q 2023) Third quarter 2024 results: EPS: kr0.21 (up from kr0.048 in 3Q 2023). Revenue: kr48.5m (up 61% from 3Q 2023). Net income: kr13.8m (up 340% from 3Q 2023). Profit margin: 28% (up from 10% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Sep 26
Genovis AB Launches Fabricator® Xtra Genovis AB announced the launch of FabRICATOR Xtra, the second generation of its widely used FabRICATOR (IdeS) enzyme. This newly developed enzyme is specifically designed to address the evolving needs of biopharmaceutical development by efficiently digesting next-generation antibody-based therapeutics with mutations designed to enhance their therapeutic properties. New generations of antibody-based therapeutics, designed with structural mutations, have posed a challenge to traditional enzyme technologies. These therapeutic antibodies, while offering enhanced efficacy and stability, could not be digested with legacy FabRICATOR® (IdeS), preventing researchers from utilizing the efficient middle-level workflows previously enabled by the enzyme. FabRICATOR® Xtra is an innovative solution to this challenge. With its ability to precisely and efficiently digest novel engineered antibody formats, Genovis is once again advancing analytical workflows for developers of future therapeutics antibodies. The new enzyme offers the same high level of accuracy and speed that users have come to expect from FabRICATOR®, ensuring that it can seamlessly integrate into existing workflows while supporting the development of future antibody-based therapies. FabRICATOR® Xtra builds upon the success of its predecessor by maintaining the same precision, accuracy, and efficiency, while extending its utility to novel formats. Genovis remains committed to supporting the biopharmaceutical industry with innovative, high-performance tools that address the demands of modern therapeutic development. Announcement • Sep 04
Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO). Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO) on September 3, 2024.
Leinco Technologies, Inc. completed the acquisition of QED Bioscience Inc from Genovis AB (publ.) (OM:GENO) on September 3, 2024. Reported Earnings • Aug 21
Second quarter 2024 earnings released: EPS: kr0.027 (vs kr0.23 in 2Q 2023) Second quarter 2024 results: EPS: kr0.027 (down from kr0.23 in 2Q 2023). Revenue: kr30.7m (up 4.3% from 2Q 2023). Net income: kr1.79m (down 88% from 2Q 2023). Profit margin: 5.8% (down from 52% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €2.80, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 41% over the past three years. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €2.87, the stock trades at a forward P/E ratio of 72x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 33% over the past three years. Reported Earnings • Apr 26
Full year 2023 earnings released: EPS: kr0.94 (vs kr0.17 in FY 2022) Full year 2023 results: EPS: kr0.94 (up from kr0.17 in FY 2022). Revenue: kr159.1m (up 54% from FY 2022). Net income: kr61.5m (up 450% from FY 2022). Profit margin: 39% (up from 11% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 4 Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €2.51, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.55 per share. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €2.73, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.41 per share. New Risk • Mar 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 5.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Feb 16
Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024 Genovis AB (publ.) announced that they will report fiscal year 2023 final results on Apr 24, 2024 Reported Earnings • Feb 16
Full year 2023 earnings released: EPS: kr0.94 (vs kr0.17 in FY 2022) Full year 2023 results: EPS: kr0.94 (up from kr0.17 in FY 2022). Revenue: kr163.6m (up 58% from FY 2022). Net income: kr61.5m (up 450% from FY 2022). Profit margin: 38% (up from 11% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Feb 12
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). New Risk • Nov 21
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Significant insider selling over the past 3 months (€2.2m sold). Reported Earnings • Nov 17
Third quarter 2023 earnings released: EPS: kr0.048 (vs kr0.087 in 3Q 2022) Third quarter 2023 results: EPS: kr0.048 (down from kr0.087 in 3Q 2022). Revenue: kr31.4m (up 37% from 3Q 2022). Net income: kr3.14m (down 45% from 3Q 2022). Profit margin: 10.0% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Oct 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be €4.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 72%. Revenue is forecast to grow by 132% in 2 years. Earnings is forecast to grow by 159% in the next 2 years. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €3.21, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total loss to shareholders of 2.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.73 per share. Announcement • Sep 05
Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024 Genovis AB (publ.) announced that they will report Q1, 2024 results on May 15, 2024 Recent Insider Transactions • Aug 30
Director recently sold €2.2m worth of stock On the 28th of August, Mikael Lonn sold around 500k shares on-market at roughly €4.47 per share. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.1m more than they bought in the last 12 months. New Risk • Aug 25
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Jun 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €3.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 30x in the Life Sciences industry in Europe. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.15 per share. Announcement • Jun 03
Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets Genovis announced the launch of its cutting-edge IgM-specific protease. This highly efficient and specific enzyme holds significant potential within various life science sectors, including research, diagnostics and therapeutic applications. The newly developed IgM-specific protease demonstrates a remarkable level of effectiveness, exhibiting exceptional specificity towards IgM antibodies, which play a critical role in the early stages of immune response. These characteristics positions the enzyme as a valuable tool for cutting-edge research and diagnostic applications, providing researchers and diagnostic professionals with enhanced precision and accuracy in their investigations. Moreover, data strongly suggest that the prevalence of neutralizing antibodies targeting the IgM protease among the human population is very low. This finding paves the way for potential therapeutic uses of the enzyme in diverse areas, including the treatment of cancer and autoimmune diseases. The enzyme's specific targeting of IgM presents an exciting opportunity to explore novel therapeutic strategies and open new possibilities for advancing the development of innovative treatments. As part of its commitment to advancing life science research and supporting the healthcare community, Genovis plans to collaborate with leading academic institutions, research organizations, and industry partners to explore the full scope of the IgM-specific protease's applications. Reported Earnings • Apr 30
Full year 2022 earnings released: EPS: kr0.17 (vs kr0.38 in FY 2021) Full year 2022 results: EPS: kr0.17 (down from kr0.38 in FY 2021). Revenue: kr103.6m (up 11% from FY 2021). Net income: kr11.2m (down 55% from FY 2021). Profit margin: 11% (down from 27% in FY 2021). Post-clinical trial products Launched (during full year): 4 Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 17
Full year 2022 earnings released: EPS: kr0.17 (vs kr0.38 in FY 2021) Full year 2022 results: EPS: kr0.17 (down from kr0.38 in FY 2021). Revenue: kr112.1m (up 21% from FY 2021). Net income: kr11.2m (down 55% from FY 2021). Profit margin: 10.0% (down from 27% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Announcement • Jan 17
Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024 Genovis AB (publ.) announced that they will report fiscal year 2023 results on Feb 15, 2024 Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 18% share price gain to €4.54, the stock trades at a forward P/E ratio of 60x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 87% over the past three years. Reported Earnings • Nov 17
Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021) Third quarter 2022 results: EPS: kr0.087 (up from kr0.013 in 3Q 2021). Revenue: kr27.0m (up 72% from 3Q 2021). Net income: kr5.71m (up kr4.85m from 3Q 2021). Profit margin: 21% (up from 5.4% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €3.64, the stock trades at a forward P/E ratio of 69x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 93% over the past three years. Reported Earnings • Aug 13
Second quarter 2022 earnings released: EPS: kr0.01 (vs kr0.016 in 2Q 2021) Second quarter 2022 results: EPS: kr0.01 (down from kr0.016 in 2Q 2021). Revenue: kr25.0m (up 28% from 2Q 2021). Net income: kr672.0k (down 36% from 2Q 2021). Profit margin: 2.7% (down from 5.4% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 19%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth. Announcement • Aug 13
Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023 Genovis AB (publ.) announced that they will report Q1, 2023 results on May 16, 2023 Announcement • May 13
Genovis AB (Publ.) Announces Board Changes Genovis AB (publ.) announced that at its AGM held on May 12, 2022, the shareholders elected Magnus Gustafsson as new board member and Torben Jørgensen elected chairperson of the board. Reported Earnings • Apr 28
First quarter 2022 earnings released: EPS: kr0.19 (vs kr0.011 in 1Q 2021) First quarter 2022 results: EPS: kr0.19 (up from kr0.011 in 1Q 2021). Revenue: kr34.0m (up 116% from 1Q 2021). Net income: kr12.3m (up kr11.6m from 1Q 2021). Profit margin: 36% (up from 4.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 23
Full year 2021 earnings released: EPS: kr0.38 (vs kr0.099 in FY 2020) Full year 2021 results: EPS: kr0.38 (up from kr0.099 in FY 2020). Revenue: kr93.0m (up 52% from FY 2020). Net income: kr24.8m (up 284% from FY 2020). Profit margin: 27% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 6 Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Announcement • Apr 07
Genovis AB (publ.), Annual General Meeting, May 12, 2022 Genovis AB (publ.), Annual General Meeting, May 12, 2022. Agenda: To consider Election of Chairman of the Meeting; to consider Election of two persons to verify the minutes; to consider Preparation and approval of voting list; to consider approval of the agenda; to consider Consideration of whether the meeting had been duly convened; to consider Determination of number of members of the Board and deputy members; and to discus other matters. Recent Insider Transactions • Mar 24
Insider recently bought €5.0k worth of stock On the 17th of March, Jonathan Sjogren bought around 1k shares on-market at roughly €4.97 per share. In the last 3 months, there was an even bigger purchase from another insider worth €30k. Insiders have collectively bought €155k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 22
Insider recently bought €5.0k worth of stock On the 17th of March, Jonathan Sjogren bought around 1k shares on-market at roughly €4.97 per share. In the last 3 months, there was an even bigger purchase from another insider worth €30k. Insiders have collectively bought €155k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 09
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: kr0.38 (up from kr0.099 in FY 2020). Revenue: kr97.3m (up 60% from FY 2020). Net income: kr24.8m (up 284% from FY 2020). Profit margin: 26% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 25%. Over the next year, revenue is forecast to grow 47%, compared to a 44% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has increased by 87% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 13
Third quarter 2021 earnings released: EPS kr0.013 (vs kr0.02 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr17.6m (up 24% from 3Q 2020). Net income: kr854.0k (down 34% from 3Q 2020). Profit margin: 4.8% (down from 9.2% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS kr0.016 (vs kr0.023 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr21.2m (up 37% from 2Q 2020). Net income: kr1.05m (up kr2.57m from 2Q 2020). Profit margin: 4.9% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has increased by 114% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 06
General Counsel recently bought €20k worth of stock On the 28th of May, Susanne Ahlberg bought around 5k shares on-market at roughly €4.14 per share. In the last 3 months, they made an even bigger purchase worth €50k. Insiders have collectively bought €129k more in shares than they have sold in the last 12 months. Reported Earnings • May 01
First quarter 2021 earnings released: EPS kr0.011 (vs kr0.031 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr15.9m (up 39% from 1Q 2020). Net income: kr740.0k (up kr2.75m from 1Q 2020). Profit margin: 4.6% (up from net loss in 1Q 2020). Reported Earnings • Feb 13
Full year 2020 earnings released: EPS kr0.099 (vs kr0.15 in FY 2019) The company reported a poor full year result with weaker earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: kr61.0m (flat on FY 2019). Net income: kr6.45m (down 33% from FY 2019). Profit margin: 11% (down from 16% in FY 2019). Analyst Estimate Surprise Post Earnings • Feb 13
Revenue beats expectations Revenue exceeded analyst estimates by 4.0%. Over the next year, revenue is forecast to grow 34%, compared to a 28% growth forecast for the Life Sciences industry in Germany. Is New 90 Day High Low • Feb 12
New 90-day high: €4.62 The company is up 55% from its price of €2.97 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period. Announcement • Feb 11
Genovis AB (publ.) to Report Nine Months, 2021 Results on Nov 11, 2021 Genovis AB (publ.) announced that they will report nine months, 2021 results on Nov 11, 2021 Is New 90 Day High Low • Jan 04
New 90-day high: €3.46 The company is up 5.0% from its price of €3.30 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 1.0% over the same period. Announcement • Dec 11
Genovis AB and Glykos Finland Oy Partner to Enable New ADC Platform Genovis AB and Glykos Finland Oy have entered into a licensing and supply agreement for linker-payload technologies to be combined with the site-specific antibody conjugation platform offered by Genovis.
By using GlyCLICK, a site-specific antibody conjugation technology from Genovis and the novel linker and cytotoxic drug derivatives from Glykos, Genovis will offer biopharma customers a platform to screen and develop Antibody Drug Conjugates (ADCs) with improved performance. The partnership between Genovis and Glykos will enable scientists around the world to build ADCs from any off-the-shelf antibody, resulting in highly defined end products. With Glykos unique linker and payload technologies, the company can now offer the biopharma community a platform to rapidly transform any antibody into an advanced site-specific antibody drug conjugate. This enables customers to explore new ways to develop ADCs which further broaden market offering, says Fredrik Olsson CEO of Genovis. With Genovis industry leading antibody processing enzymes and the GlyCLICK platform, collaboration with Genovis opens new user base to linker-payload ADC technologies. The combined product enables scientists to efficiently generate ADCs from their pipeline antibodies and to assess their functionality as unique research tools and potential therapeutics, says Juhani Saarinen CEO of Glykos. The new GlyCLICK ADC products are available for purchase globally on December 10, 2020 through Genovis and distributors. Analyst Estimate Surprise Post Earnings • Nov 11
Revenue misses expectations Revenue missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 102%, compared to a 17% growth forecast for the Life Sciences industry in Germany. Reported Earnings • Nov 11
Third quarter 2020 earnings released: EPS kr0.02 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: kr14.5m (down 40% from 3Q 2019). Net income: kr1.30m (down 82% from 3Q 2019). Profit margin: 9.0% (down from 30% in 3Q 2019). The decrease in margin was driven by lower revenue. Is New 90 Day High Low • Oct 24
New 90-day low: €2.95 The company is down 19% from its price of €3.64 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.91 per share. Announcement • Aug 14
Genovis AB (publ.) to Report First Half, 2021 Results on Aug 12, 2021 Genovis AB (publ.) announced that they will report first half, 2021 results on Aug 12, 2021 Announcement • Jul 31
Genovis AB (publ) (OM:GENO) completed the acquisition of QED Bioscience, Inc. Genovis AB (publ) (OM:GENO) signed a Letter of Intent to acquire QED Bioscience, Inc. for approximately SEK 20 million on February 20, 2020. The transaction will be financed through the amount raised by the Genovis’ rights issue of SEK 50 million. QED Bioscience's team will be retained by Genovis. The transaction is subject to the customary terms and conditions. The acquisition is expected to be completed during the first quarter of 2020.
Genovis AB (publ) (OM:GENO) completed the acquisition of QED Bioscience, Inc. on April 29, 2020. 
